Диссертация (1155054), страница 34
Текст из файла (страница 34)
Vol. 211 / E. Nogales, S.G. Wolf, K.H. Downing; eds. T.E.Weirich, J.L. Lábár, X. Zou. – Berlin/Heidelberg: Springer-Verlag, 2006. – 199-204 p.doi:10.1007/1-4020-3920-4.179. Oncolytic Virotherapy for the Treatment of Malignant Glioma / P.M. Foreman,206G.K. Friedman, K.A. Cassady [et al.] // Neurotherapeutics. – 2017.
– Vol. 14. – № 2. –P. 333-344 doi:10.1007/s13311-017-0516-0.180. Ornamental Exterior versus Therapeutic Interior of Madagascar Periwinkle (Catharanthus roseus ): The Two Faces of a Versatile Herb / N. Nejat, A. Valdiani, D.Cahill [et al.] // The Scientific World Journal. – 2015. – Vol. 2015.
– P. 1-19doi:10.1155/2015/982412.181. Owellen R.J. Pharmacokinetics and Metabolism of Vinblastine in Humans / R.J.Owellen, C. a Hartke, F. Hams // Cancer Research. – 1977. – № August. – P. 25972602.182. Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomesin the General Population / A.G. Robinson, X. Wei, F.E. Vera-Badillo [et al.] //ClinicalGenitourinaryCancer.–2016.–Vol. 16.–P. 30371-30378doi:10.1016/j.clgc.2016.12.025.183. Patel R.P.
An overview of resealed erythrocyte drug delivery / R.P. Patel, M.J.Patel, N. a. Patel // Journal of Pharmacy Research. – 2009. – Vol. 2. – № 6. – P. 10081012.184. Patterns and severity of vincristine-induced peripheral neuropathy in childrenwith acute lymphoblastic leukemia / E.M. Lavoie Smith, L. Li, C. Chiang [et al.] //Journal of the Peripheral Nervous System. – 2015. – Vol. 20. – P.
37-46.185. PEGylation of nanoparticles improves their cytoplasmic transport. / J. Suh, K.-L.Choy, S.K. Lai [et al.] // International journal of nanomedicine. – 2007. – Vol. 2. –№ 4. – P. 735-41.186. Perche F. Recent Trends in Multifunctional Liposomal Nanocarriers forEnhanced Tumor Targeting / F. Perche, V.P. Torchilin // Journal of Drug Delivery. –2013. – Vol. 2013.
– P. 1-32 doi:10.1155/2013/705265.187. Pharmacokinetic behavior of vincristine sulfate following administration ofvincristine sulfate liposome injection / L. Embree, K. Gelmon, A. Tolcher [et al.] //207Cancer Chemotherapy and Pharmacology. – 1998. – Vol. 41. – № 5. – P. 347-352doi:10.1007/s002800050750.188.
Pharmacokinetic characteristics of vincristine sulfate liposomes in patients withadvanced solid tumors / Z. Yan, Z. Zhu, Z. Qian [et al.] // Acta Pharmacologica Sinica.– 2012. – Vol. 33. – № 6. – P. 852-858 doi:10.1038/aps.2012.44.189. Pharmacokinetics of vincristine in cancer patients treated with nifedipine / L.Fedeli, M. Colozza, E.
Boschetti [et al.] // Cancer. – 1989. – Vol. 64. – № 9. – P. 18051811doi:10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO;2-D.190. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) inJapanese patients with advanced melanoma (KEYNOTE-041) / N. Yamazaki, T.Takenouchi, M. Fujimoto [et al.] // Cancer Chemotherapy and Pharmacology. – 2017.– Vol.
79. – № 4. – P. 651-660 doi:10.1007/s00280-016-3237-x.191. Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin inadvanced non-small cell lung cancer / A.Y.-C. Chang, J. Philip Kuebler, D.C. Tormey[et al.] // Cancer. – 1986. – Vol. 57. – № 1. – P. 54-59 doi:10.1002/10970142(19860101)57:1<54::AID-CNCR2820570112>3.0.CO;2-D.192.
Potentiation of vincristine toxicity by itraconazole in children with lymphoidmalignancies / M. Kamaluddin, P. McNally, F. Breatnach [et al.] // Acta Paediatrica. –2001. – Vol. 90. – № 10. – P. 1204-1207 doi:10.1080/080352501317061675.193. Preparation and Properties of Various Magnetic Nanoparticles / J. Drbohlavova,R. Hrdy, V. Adam [et al.] // Sensors. – 2009. – Vol. 9. – № 4. – P.
2352-2362doi:10.3390/s90402352.194. Preparation of vincristine sulfate-loaded poly (butylcyanoacrylate) nanoparticlesmodified with pluronic F127 and evaluation of their lymphatic tissue targeting / R.Tan, M. Niu, J. Zhao [et al.] // Journal of Drug Targeting. – 2014. – Vol. 22.
– № 6. –P. 509-517 doi:10.3109/1061186X.2014.897708.208195. Prokop A. Intracellular Delivery: Fundamentals and Applications : FundamentalBiomedical Technologies. Vol. 5 / A. Prokop; ed. A. Prokop. – Dordrecht: SpringerNetherlands, 2011. – 888 p. doi:10.1007/978-94-007-1248-5.196. Protein-Based Multifunctional Nanocarriers for Imaging, Photothermal Therapy,and Anticancer Drug Delivery / U.N. Pan, R. Khandelia, P.
Sanpui [et al.] // ACSApplied Materials & Interfaces. – 2017. – Vol. 9. – № 23. – P. 19495-19501doi:10.1021/acsami.6b06099.197. Raderer M. Re: Vinorelbine-Induced Pancreatitis: a Case Report / M. Raderer, G.Kornek, W. Scheithauer // JNCI Journal of the National Cancer Institute. – 1998. –Vol. 90. – № 4. – P.
329-329 doi:10.1093/jnci/90.4.329.198. Ranta V.-P. Electrochemical Detection of Alkaloids in HPLC / V.-P. Ranta, J.C.Callaway, T. Naaranlahti // ALKALOIDS / ed. J.F. Jackson, Hans Ferdinand Linskens.– Springer-Verlag Berlin Heidelberg, 1994. – Vol. 15. – P. 91-114 doi:10.1007/978-3642-84226-9_3.199. Rapid identification of vinca alkaloids by direct-injection electrospray ionisationtandemmassspectrometryandconfirmationbyhigh-performanceliquidchromatography-mass spectrometry / H. Zhou, Y.
Tai, C. Sun [et al.] // Phytochemicalanalysis : PCA. – 2005. – Vol. 16. – № 5. – P. 328-33 doi:10.1002/pca.852.200. Ravilla S. Erythrocytes as Carrier for Drugs, Enzymes and Peptides / S. Ravilla //journal of applied pharmaceutical science. – 2012. – Vol. 2. – № 4. – P. 166-176doi:10.7324/JAPS.2012.2503.201. Raymond C Rowe.
Mannitol / Raymond C Rowe, P.J. Sheskey, S.C. Owen //Handbook of Pharmaceutical Excipients. – London: Pharmaceutical press, 2012. –P. 479-482.202. Recent advancements in erythrocytes, platelets, and albumin asdelivery systems / P. Xu, R. Wang, X. Wang [et al.] // OncoTargets and Therapy. –2016. – Vol. 9. – P. 2873 doi:10.2147/OTT.S104691.209203. Rechsteiner M.C. Uptake of proteins by red blood cells / M.C.
Rechsteiner //ExperimentalCellResearch. –1975. –Vol. 93.–№ 2.–P. 487-492doi:10.1016/0014-4827(75)90478-4.204. Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles andinspiration for advanced delivery systems / C.H. Villa, A.C. Anselmo, S.
Mitragotri [etal.] // Advanced Drug Delivery Reviews. – 2016. – Vol. 106. – P. 88-103doi:10.1016/j.addr.2016.02.007.205. Reengineering red blood cells for cellular therapeutics and diagnostics / F.Pierig?, N. Bigini, L. Rossi [et al.] // Wiley Interdisciplinary Reviews: Nanomedicineand Nanobiotechnology. – 2017. – P.
e1454 doi:10.1002/wnan.1454.206. Resealed erythrocytes: A Novel carrier for drug targeting / A.K. Sah, A.Rambhade, A. Ram [et al.] // Journal of Chemical and Pharmaceutical Research. –2011. – Vol. 3. – № 2. – P. 550-565.207. Review Article Drug Targeting By Erythrocytes : A Carrier System / K.V.Saurabh, S. Rani, S. Rani [et al.].
– 2013. – Vol. 2. – № 2. – P. 144-156.208. Ross M.H. Blood / M.H. Ross, W. Pawlina // A Text and Atlas: With CorrelatedCell and Molecular Biology, 6th Edition / eds. M.H. Ross, W. Pawlina. – WolterKluwer, 2011. – P. 270-313.209. Rubomycin loaded erythrocytes in the treatment of mouse tumor P388. / F.I.Ataullakhanov, V.M. Vitvitsky, V.L. Kovaleva [et al.] // Advances in experimentalmedicine and biology.
– 1992. – Vol. 326. – P. 209-13.210.Seigneuret M.ATP-dependentasymmetricdistributionofspin-labeledphospholipids in the erythrocyte membrane: relation to shape changes / M. Seigneuret,P.F. Devaux // Proceedings of the National Academy of Sciences. – 1984. – Vol. 81. –№ 12. – P.
3751-3755 doi:10.1073/pnas.81.12.3751.211. Selective metabolism of vincristine in vitro by CYP3A5 / J.B. Dennison, P.Kulanthaivel, R.J. Barbuch [et al.] // Drug metabolism and disposition: the biological210fateofchemicals.–2006.–Vol. 34.–№ 8.–P. 1317-27doi:10.1124/dmd.106.009902.212. Sethi V.S. A sensitive radioimmunoassay for vincristine and vinblastine.
/ V.S.Sethi, S.S. Burton, D. V Jackson // Cancer chemotherapy and pharmacology. – 1980. –Vol. 4. – № 3. – P. 183-187 doi:10.1007/BF00254016.213. Sethi V.S. Cancer Chemotherapy and Pharmacology Pharmacokinetics ofVincristine Sulfate in Children / V.S. Sethi, J.C.
Kimball // Cancer Chemotherapy andPharmacology. – 1981. – Vol. 6. – P. 111-115.214. Sethi V.S. Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesusmonkeys / V.S. Sethi, P. Surratt, C.L. Spurr // Cancer Chemother Pharmacol. – 1984. –Vol.
12. – P. 31-35.215. Sethi V.S. Structural Studies on the Degradation Products of VincristineDihydrogen Sulfate / V.S. Sethi, K.N. Thimmaiah // Cancer Research. – 1985. –Vol. 45. – № November. – P. 5386-5389.216. Sheetz M.P. On the mechanism of ATP-induced shape changes in humanerythrocyte membranes. I. The role of the spectrin complex / M.P.
Sheetz, S.J. Singer// The Journal of cell biology. – 1977. – Vol. 73. – № 3. – P. 638-46doi:10.1083/jcb.73.3.638.217. Shegokar R. Applications of Cell-Based Drug Delivery Systems: Use of SingleCell Assay / R. Shegokar, S. Sawant, L. Al Shaal // Essentials of Single-Cell Analysis :Series in BioEngineering / eds. F.-G.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
